Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

Go back to Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders
(NASDAQ: IKT) Delayed: 5.40 +0.27 (5.26%)
Previous Close $5.13    52 Week High
Open $5.14    52 Week Low
Day High $5.85    P/E N/A 
Day Low $5.14    EPS
Volume 39,778